{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals Hits Day Low of $7.27 Amid Price Pressure
Day One Biopharmaceuticals, Inc. faced notable challenges on October 6, 2025, with a significant stock decline. Despite a substantial increase in net sales last quarter, the company has struggled with long-term growth and negative operating cash flow, raising concerns about its financial health and market position.
Day One Biopharmaceuticals Experiences Evaluation Revision Amidst Market Challenges and Mixed Performance Indicators
Day One Biopharmaceuticals, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $6.77. Over the past year, the company has experienced a significant decline, contrasting sharply with the S&P 500's performance. Technical indicators show mixed signals, reflecting varied momentum and potential volatility.
Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?
As of September 26, 2025, Day One Biopharmaceuticals, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -46.57% versus the benchmark's 12.96%.
Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?
As of September 26, 2025, Day One Biopharmaceuticals, Inc. shows a mildly bearish trend overall, with mixed indicators across different timeframes, including a mildly bullish weekly MACD and bearish monthly signals, while underperforming against the S&P 500.
Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?
As of September 26, 2025, Day One Biopharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators and has significantly underperformed the S&P 500, with year-to-date and one-year returns of -46.57% and -52.62%, respectively.
Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?
As of August 12, 2025, Day One Biopharmaceuticals, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while the stock has significantly underperformed the S&P 500, showing a year-to-date return of -43.09% compared to the S&P 500's 12.22%.
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?
As of July 30, 2024, Day One Biopharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics and a year-to-date return of -43.09%, underperforming the S&P 500's 12.22%.
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?
As of July 30, 2024, Day One Biopharmaceuticals, Inc. is deemed "risky" and overvalued with a Price to Book Value of 1.52 and an EV to Sales ratio of 1.58, significantly underperforming peers like Catalyst Pharmaceuticals and MannKind Corp., and has a year-to-date return of -48.86% compared to the S&P 500's 2.44%.
Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?
As of June 3, 2025, the technical trend is mildly bearish, with mixed signals from indicators like the MACD, RSI, and moving averages suggesting a cautious outlook.
What does Day One Biopharmaceuticals, Inc. do?
Day One Biopharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $31 million and a net loss of $36 million as of March 2025. The company has a market cap of $658.86 million and does not pay dividends.
How big is Day One Biopharmaceuticals, Inc.?
As of Jun 18, Day One Biopharmaceuticals, Inc. has a market capitalization of 658.86 million and reported net sales of 161.92 million with a net loss of 69.08 million. Shareholder's funds are 502.75 million, and total assets amount to 582.79 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
